GlassScriptPhysician profile
Hemant T Thawani
NPI 1770545964
$306.19
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $44.65 · 2021: $64.58 · 2022: $63.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $128.42 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $72.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $39.41 | 2019 | |
| Melinta Therapeutics, LLC | $22.63 | 2019 | |
| Cepheid | $17.15 | 2022 | |
| Amgen INC. | $13.89 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemant Thawani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.